Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E W Humke

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Chemistry & Biology|February 7, 2001
Web Alert. ApoptosisE W Humke
The Journal of Biological Chemistry|June 23, 1998
ERICE, a novel FLICE-activatable caspaseE W Humke, J Ni, V M Dixit
FEBS Letters|May 23, 1998
Activation of caspases triggered by cytochrome c in vitroG Pan, E W Humke, V M Dixit
Cellular and Molecular Neurobiology|October 1, 1994
Modulation of the PC12 cell response to nerve growth factor by antisense oligonucleotide to amyloid precursor proteinR E Majocha, S Agrawal, J Y Tang, et al.
Cell|October 29, 2000
ICEBERG: a novel inhibitor of interleukin-1beta generationE W Humke, S K Shriver, M A Starovasnik, et al.
Communications Biology|February 20, 2024
The exocyst complex and intracellular vesicles mediate soluble protein trafficking to the primary ciliumS M Niedziółka, S Datta, T Uśpieński, et al.
The Journal of Biological Chemistry|March 20, 1999
Caspase-9 can be activated without proteolytic processingH R Stennicke, Q L Deveraux, E W Humke, et al.
Protein Science : a Publication of the Protein Society|August 22, 2001
The PYRIN domain: a member of the death domain-fold superfamilyW J Fairbrother, N C Gordon, E W Humke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II studyS Banerjee, A M Oza, M J Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancerJ F Liu, K N Moore, M J Birrer, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Chemistry & Biology|February 7, 2001
Web Alert. ApoptosisE W Humke
The Journal of Biological Chemistry|June 23, 1998
ERICE, a novel FLICE-activatable caspaseE W Humke, J Ni, V M Dixit
FEBS Letters|May 23, 1998
Activation of caspases triggered by cytochrome c in vitroG Pan, E W Humke, V M Dixit
Cellular and Molecular Neurobiology|October 1, 1994
Modulation of the PC12 cell response to nerve growth factor by antisense oligonucleotide to amyloid precursor proteinR E Majocha, S Agrawal, J Y Tang, et al.
Cell|October 29, 2000
ICEBERG: a novel inhibitor of interleukin-1beta generationE W Humke, S K Shriver, M A Starovasnik, et al.
Communications Biology|February 20, 2024
The exocyst complex and intracellular vesicles mediate soluble protein trafficking to the primary ciliumS M Niedziółka, S Datta, T Uśpieński, et al.
The Journal of Biological Chemistry|March 20, 1999
Caspase-9 can be activated without proteolytic processingH R Stennicke, Q L Deveraux, E W Humke, et al.
Protein Science : a Publication of the Protein Society|August 22, 2001
The PYRIN domain: a member of the death domain-fold superfamilyW J Fairbrother, N C Gordon, E W Humke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II studyS Banerjee, A M Oza, M J Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancerJ F Liu, K N Moore, M J Birrer, et al.
Pageof 1